Crinetics (CRNX) CFO Schilke Tobin Receives Restricted Stock Award

What Happened

• Schilke Tobin, Chief Financial Officer of Crinetics Pharmaceuticals (CRNX), was granted 471 restricted stock units (reported as an "A" award) on August 20, 2026. The units were reported at $0.00 per share (total reported value $0). This is an issuance of equity compensation (an award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-20; Filing date: 2026-08-24.
• Award: 471 RSUs reported at $0.00 per share (total $0).
• Vesting: Footnote F1 — the RSUs represent the right to receive common stock and vest 25% annually beginning September 1, 2027.
• Ownership/other shares: Footnote F2 notes 835 shares were acquired under the company’s Employee Stock Purchase Plan and are included in reported holdings (ownership totals not specified in the provided excerpt).
• Filing timeliness: filing date is shown as Aug 24, 2026; the excerpt does not specify a late-filing flag.

Context

• RSU grants are standard executive compensation and do not reflect an immediate cash purchase or sale. The units will convert to shares only as they vest per the stated schedule. For retail investors, awards indicate how the company compensates executives but are not direct indicators of buying or selling sentiment by the insider.